Skip to main content

Rare Lung Diseases Center News

Children with rare lung diseases benefit from our world-leading experts for diagnosis and treatment.

Contact us

In the Journals: Nirsevimab

Jan 18, 2024

Find out about the results of a prospective, placebo-controlled trial in 8,058 healthy infants that served as the basis for licensure of nirsevimab.

Jump back to top